BIMO meeting update
This article was originally published in The Gray Sheet
Executive Summary
FDLI-coordinated bioresearch monitoring meeting planned for June 10-11 to aid development of draft guidance on good monitoring practices (1"The Gray Sheet" April 26, 2004, p. 9). The invitation-only stakeholder discussion is expected to include about 20 reps from small, medium and large device firms, contract research organizations, consulting firms and law firms...
You may also be interested in...
Device Firms Struggling With Trial Monitoring Could Receive BIMO Guidance
FDA's Division of Bioresearch Monitoring will convene a June meeting of industry stakeholders to commence development of a best practices guidance for medical device clinical trial monitoring
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.